Precipio, Inc. · NASDAQ:PRPO
Precipio — Investor Presentation (June 2022)
12 slides from Precipio's investor presentation, Jun 13, 2022
Slide 1: 2022 Corporate Presentation
Page (NASDAQ: PRPO) A Cancer Diagnostics Solutions Company 2022 Corporate Presentation DISCLAIMER This presentation has been prepared by Precipio Inc.(the “Company”) and is general background information about the Company’s activities as of the date of this presentation. By accepting this presentati
Slide 2: Market problem
Page Market problem Diagnostic errors cost $750B* annually in the US market * Patient Safety Learning White paper publication by PinnacleCare And countless lives. 2
Slide 3: Company Vision
Page Company Vision Creating clinically significant, cost-effective cancer diagnostic technologies to eliminate laboratory errors 3
Slide 4: Unique Business Model
Page Unique Business Model Solving Clinical, Operational, & Economic Challenges for Diagnostic Laboratories • Precipio identifies clinical and operational challenges • Facilitates the development, testing and implementations of new technologies Clinical Laboratory • Collaborates with the clinical la
Slide 5: Solution: HemeScreen
Page Solution A set of proprietary reagents using a single-platform, delivering faster and more accurate results TAM $500M in the US $1B worldwide Commercial status 5 commercial panels 3 panels in development YE2021 RR: ~$2M est. 25% QoQ growth Hemescreen™ - Molecular Assays solving economic, workfl
Slide 6: HemeScreen Benefits: Case Study
Page 18 days TAT (send-out) reduced to 1-2 days (in house) Broad panel enables more precise, targeted treatments Shorter TAT drives a faster response and better patient care Zero revenues, to ~$1M/year in operating profit (currently one panel only) HemeScreen Benefits Turnaround Time (TAT) Patient I
Slide 7: Solution: IV-Cell Cytogenetics Cell Culture Media
Page Solution A proprietary media (chemical) used to simultaneously culture multiple types of suspected cancer cells, eliminating diagnostic errors due to pre- selection TAM $100M in the US $250M worldwide Commercial status Products for hematologic cancers available. Products for prenatal testing un
Slide 8: Channel Distribution Strategy
Page Channel Distribution Strategy Leveraging existing channel distributors HemeScreen Segments: Benefits: Rapid direct access to target market Reduces time to market Avoids costly sales team IV-Cell Segments: 90% 10% TAM: $100M US $250M Globally Physician owned laboratories Reference laboratories H
Slide 9: R&D Product Pipeline
Page A novel technology enabling accurate assessment of Minimal Residual Disease on limited samples $3B Annually In process – expected completion Q2-2023 Product 4: Cancer MRD Enriches target DNA in samples to significantly reduce biopsy rejection rate $0.5B Annually In process – expected completion
Slide 10: Management Team
Page Having served as co-founder and CEO since 2011, Ilan brings over 25 years of experience managing small and medium-size companies. Past experiences include COO of Osiris, VP of Operations at Laurus Capital Management, a multi billion-dollar hedge fund, as well as in various other entrepreneurial
Slide 11: Board and Advisors
Page Richard is a seasoned diagnostics executive with a substantial track record in field. Having served and acted in multiple roles at Dianon Systems, Inc., a diagnostics company that was acquired by LabCorp for $650M, along with Oxford Immunotec, acquired by PerkinElmer for $550M, his depth and ex
Slide 12: Summary
Page Established R&D platform to develop practical, efficient diagnostic solutions Two commercially available, revenue generating products Robust R&D pipeline of impactful cancer diagnostic products, each with billion dollar TAMs Revenue-generating clinical lab creates a self-funded R&D center For m